Project Grant R43AI167394
Award Date
7/8/22
Completion Date
6/30/23
Dollars Obligated
$597K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
CRYSTAL CITY, CA 90220, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Inhalon Biopharma, Inc. a $1,024,926 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to complete non-clinical activities associated with a Phase 1 clinical study for their inhaled monoclonal antibody therapy, IN-002, targeted at treating respiratory syncytial virus (RSV) infections. The funded activities include processing clinical trial biospecimens to determine drug levels,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,024,942 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Inhalon Biopharma, Inc. to support the development of an inhaled monoclonal antibody therapy called IN-003 for treating human metapneumovirus (MPV) infection. The grant funding will enable Inhalon to produce a GLP-compliant batch of the IN-003 antibody treatment and conduct key IND-enabling studies required by the FDA before advancing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $143,450 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Sigmovir Biosystems, Inc. (SBI), a Maryland-based biotechnology company, with a period of performance from August 1, 2024 to June 30, 2026.
The grant funding supports SBI's research to evaluate the therapeutic efficacy of combinations of PPARG agonist and RXR ligand compounds in treating viral-induced acute lung injury,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is supporting the development of a novel nitric oxide-releasing drug formulation (ALX1) to treat Pseudomonas aeruginosa lung infections in bronchiectasis patients. The $1,000,000 award to Vast Therapeutics, Inc. aims to enhance the product quality and stability of ALX1, identify optimal dosing regimens in preclinical models, and evaluate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to Scientific Horizons Consulting LLC will support research into a novel antibiotic delivery system using cyclodextrin-based metal-organic frameworks (CD-MOFs) to treat non-tuberculous mycobacterial (NTM) lung infections. The $298,530 award, effective July 1, 2024 through June 30, 2025, will fund the development and evaluation of antibiotic/CD-MOF...
This $295,700 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel combination therapy for treating muco-obstructive lung diseases, such as COPD and asthma. The primary product or service being developed is a combination therapy involving an ENaC blocker (P-1155) and an osmolyte. The funding will be used to conduct formulation and stability studies, evaluate efficacy...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,900,450 to Pop Biotechnologies Inc., a small disadvantaged business, to advance the development and testing of a hexavalent adjuvanted influenza vaccine platform.
The key products and services to be delivered under this award include:
Production and characterization of the SNAP-FLU nanoparticle vaccine candidate, which combines trimeric...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit limited liability company in Austin, Texas. The purpose of this 11-month grant is to develop a stable, aerosolizable dry powder formulation of bacteriophages (D29 phages) encapsulated in polymeric microparticles for the treatment of pulmonary tuberculosis (TB) infections. The key...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded VRM Labs, Inc. a $3,075,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel disinfectant solution capable of forming a durable antimicrobial film for frequently touched surfaces. The goal is to collect data required for regulatory approval and scale up manufacturing to commercialize this disinfectant product. The key deliverables include:
Optimizing the...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories) to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. The award has an expected completion date of December 31, 2024. Tsrl, Inc. is a pharmaceutical...